Navigation Links
First-ever covalent irreversible inhibition of a protease central to hepatitis C infection
Date:11/28/2010

structure in the HCV protease not found in human proteases. Key findings include:

  • A representative irreversible covalent inhibitor designed, by Avila, was shown to inhibit the HCV protease (also known as "NS3") in cells at a concentration of 6 nM .
  • Specific covalent bond formation between the drug and target protease was demonstrated through use of mass spectrometry and also x-ray crystallography.
  • Very high selectivity of the Avila compounds was demonstrated by showing no notable inhibition of a panel of human proteases in biochemical assays with additional specificity demonstrated in cellular assays; this was contrasted experimentally with Telaprevir, an HCV protease inhibitor in late-stage clinical testing which demonstrated off-target biochemical activity against several human targets.

Avila has subsequently optimized additional drug candidates, yielding current development candidates, AVL-181 and AVL-192, which have excellent pharmacokinetics and bind potently to wild- type HCV protease as well as multiple genotypes and mutant forms of HCV protease.


'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412
Yates Public Relations
Source:Eurekalert

Page: 1 2

Related biology news :

1. First-ever blueprint of a minimal cell is more complex than expected
2. UBC researchers find first-ever wanderlust gene in tiny bony fish
3. Afghanistan releases its first-ever list of protected species
4. UBC researcher gives first-ever estimate of worldwide fish biomass and impact on climate change
5. First-ever socioeconomic study on coral reefs points to challenges of coastal resource management
6. New clues to how cancer-related proteins plasmin, thrombin lose inhibition
7. Gene signal GS-101 data shows safe and effective inhibition of ophthalmic blood vessel growth
8. HIV-1 protease inhibitor induced oxidative stress in pancreatic B-cells: thymoquinone protection
9. Researchers describe protease inhibitor that may aid in diabetic retinopathy treatment
10. New regional facility opened to advance stable isotope research in central Appalachians
11. Barrow scientists uncover clues on inflammation in central nervous system
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... many parts of the world, leprosy and tuberculosis ... cases of leprosy per year, with nearly all ... currently available century-old vaccine Bacille Calmette-Guerin, or BCG, ... leprosy, so a more potent vaccine is needed ... found a stronger weapon against both diseases., In ...
(Date:8/19/2014)... with neonatal abstinence syndrome (NAS) secondary to in-utero ... through withdrawal than others, but the underlying reasons ... (when genes are turned on or off) changes ... at Boston University School of Medicine (BUSM) and ... its kind study to identify some of these ...
(Date:8/19/2014)... Science Center at San Antonio and The University of ... of more than $750,000 in grants through the San ... in 2003, SALSI is a model of how a ... center join forces for greater research and graduate education. ... focus on public health issues and diseases of global ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3
... Two chemicals -- trichloroethylene (TCE) and tetrachloroethylene (PCE) -- ... Base Camp Lejeune from the 1950s to 1985 have ... cancers. A new report from the National Research ... Potential Health Effects, reviews scientific evidence about the potential ...
... humans have evolved to naturally understand things like facial expressions ... found there is an ever-widening gap between what humans can ... successful adults in today,s modern society. Schools have traditionally helped ... the U.S. more may need to be done. "Schools ...
... Australian company Stadvis Pty Ltd have signed a worldwide ... predicts glycemic index (GI) and resistant starch (RS) in ... with an accurate means of testing the functional properties ... is much quicker and more cost-effective than the current ...
Cached Biology News:MU study finds connection between evolution, classroom learning 2CSIRO deal to commercialize 'artificial gut' 2
(Date:8/19/2014)... KS (PRWEB) August 19, 2014 ... offer fast and cost-effective metabolite production from bioactive ... proprietary chemistry platform, the technology enables convenient and ... According to XenoTech’s Vice President of Commercial ... synthesis for assessing clinical risk can be measured ...
(Date:8/19/2014)... VANCOUVER , Aug. 19, 2014 /PRNewswire/ - iCo ... (OTCQX: ICOTF), today reported results of its Oral ... latent HIV reservoirs.  The study, conducted by ImmuneCarta®, ... in vitro effectiveness of Oral Amp ... remain present in individuals despite intensive treatment with ...
(Date:8/18/2014)... 18, 2014 BioElectronics Corporation (OTC ... medical devices said that its EVP Dr. ... CEOLIVE.TV as part of its Executive Interview ... available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... investors the unique advantages of BioElectronics patented ...
(Date:8/18/2014)... August 18, 2014 According ... Market, By Application (Municipal Wastewater Treatment and Industrial ... and Multi Tubular), By Configuration (Internal/Submerged and External/Sidestream), ... by MarketsandMarkets, The market for membrane bioreactor systems ... growing at a CAGR of 15.28% between 2014 ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... 2011 The 10th annual Evergreen Healthcare Foundation Gala ... and friends of the hospital together at King County,s ... million to kick off a capital campaign that will ... imaging technology.   The "Evening in Paris" ...
... At this year,s American Academy of AntiAging (A4M) conference, ... leading factors in premature aging and disease. AGEs are dangerous ... sugar that attaches to a protein or lipid without the ... completely irreversible—and cause accelerated damage to the tissues and cells. ...
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA ), ... it will release its unaudited financial results for the first ... 13, 2011.  The Company will host a conference call on ... 2011 at 8:00 pm China Standard Time) to review the ...
Cached Biology Technology:Evergreen Foundation Gala Raises $1.16 Million for Cancer Care, Kicks off Capital Campaign 2At This Year's American Academy of AntiAging (A4M) Conference, Glycation and AGEs (Advanced Glycation End Products) Were Named the Leading Factors in Premature Aging and Disease 2Sinovac to Host Conference Call to Report First Quarter 2011 Unaudited Financial Results 2
Immunochemistry 1 & 2...
... A.P. Johnstone and M.W. Turner ... strategies and methods used in the ... of antibodies in immunoassays, the standardisation ... ELISA techniques including amplification systems, enzyme ...
Supplemental reagent for annexin V assay....
See product name for description....
Biology Products: